Condition: Renal Cell Carcinoma · Sponsor: Bristol-Myers Squibb
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| Arthur J.E. Child Comprehensive Cancer Centre | Calgary, Alberta, Canada | Recruiting |
| Gustave Roussy | Villejuif, Val-de-Marne, France | Recruiting |
| Hospital Universitario Reina Sofia | Córdoba, Andalusia, Spain | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Barcelona [Barcelona], Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07195682